More recently, a phase II study (IFCT 1703-R2D2, NCT03845270) also showed the efficacy of the combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced NSCLC harboring HER-2 mutations who progressed after ≥ 1 platinum-based treatment, and this combination exhibited a feasible result. Here, ERBB2 is linked to non-small cell lung carcinoma.